Inclusion Criteria:
* Age:18-75 years, male or female.
* Histologically or cytologically confirmed IIIB-IV- Advanced NSCLC
* There was a Metex 14 skipping mutation in plasma and / or tissue
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 \~2
* Life expectancy of greater than 12 weeks.
* Evaluable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
* Adequate organ function.
* Contraception, fertility and not lactating female subjects: screening blood pregnancy test must be negative
* Voluntarily join the study and sign informed consent ad has good compliance.
Exclusion Criteria:
* EGFR or ALK or ROS1 gene mutation was positive
* Anthracycline, nitrosourea, and mitomycin within 6 weeks; traditional Chinese medicine for anti-tumor within 2 weeks;other anti-tumor therapies within 4 weeks, Previously or currently participating in other clinical trials within 4 week, Prior therapies with c-MET targeted drugs; Had received vaccine within 4 weeks prior to study treatment or had a plan to receive vaccine during the trial.
* Not recovered from adverse events due to a previously administered agent.
* Symptomatic, untreated or unstable central nervous system metastases/ spinal cord compression, cancerous meningitis, or meningitis.
* Patients with other malignant tumors except NSCLC within 5 years before the first use of drugs do not include those with negligible risk of metastasis or death (such as expected 5-year OS \> 90%) and expected to be cured after treatment, or any other tumors that have been cured (no evidence of recurrence within 5 years)
* There are prescribed cardiovascular and cerebrovascular risk factors
* Patients with evidence of bleeding tendency, or melena or hematemesis within 2 months; or visceral bleeding that may occur considered by investigator
* History of thyroid dysfunction, and the thyroid function cannot be maintained at the normal range with drugs.
* There are uncontrollable and active infections
* Uncontrollable massive pleural / ascites or pericardial effusion
* Clinically significant gastrointestinal abnormalities may affect the drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy subjects;
* a history of psychotropic drug abuse and can not quit or have mental disorders
* Any other reason the investigator considers the patient is not suitable to participate in the study
